Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.248E-14 | 2.448E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.808E-12 | 4.920E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.570E-12 | 4.920E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.587E-12 | 5.841E-09 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.987E-12 | 5.913E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.665E-12 | 1.192E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.517E-11 | 1.159E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.212E-09 | 1.257E-06 | CYP1A2, CYP2C9, CYP3A4 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 6.025E-08 | 3.748E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, RAB9A |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.642E-08 | 4.018E-05 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.322E-07 | 2.897E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 7.803E-07 | 4.008E-04 | CYP19A1, CYP1A2, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.463E-06 | 6.501E-04 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.924E-06 | 1.202E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.872E-06 | 1.894E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 7.305E-06 | 2.743E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.022E-05 | 3.773E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.363E-05 | 4.864E-03 | CYP1A1, CYP1A2 |
CC | GO:0016020; membrane | GO:0031090; organelle membrane | 2.171E-05 | 7.624E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, LMNA, NPC1, RAB9A |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.738E-16 | 1.685E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.153E-11 | 3.460E-10 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.374E-10 | 5.061E-09 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.066E-10 | 6.066E-09 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.100E-09 | 8.248E-09 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.532E-09 | 2.119E-08 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.265E-07 | 6.325E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.657E-06 | 1.139E-05 | CYP1A2; CYP1A1; CYP1B1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 8.033E-06 | 2.678E-05 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP2C19; CYP3A4; CYP19A1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.249E-06 | 1.968E-05 | CYP1A1; CYP1B1; CYP19A1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.400E-04 | 2.520E-03 | CYP2C9; CYP2C19 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.707E-03 | 7.382E-03 | CYP2C9; CYP2C19 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.495E-03 | 8.739E-03 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |